Fridrik M A, Wahl G, Herbinger W
I. Department of Medicine, AKH-Linz, Austria.
Blut. 1988 Dec;57(6):357-60. doi: 10.1007/BF00320758.
Myelodysplastic syndromes (MDS) are heterogeneous diseases. Patients with blast counts of more than 20% of nucleated bone marrow cells have a high risk of short survival. We treated six patients with refractory anemia with excess of blast in transformation (RAEBiT) with low dose cytosine arabinoside (LD Ara-C). We had one partial remission (PR), surviving 16 weeks and two complete remissions (CR), surviving 22 and 55+ months. Myelosuppression was dominant in all patients, but was not as serious as with conventional remission-induction treatments for leukemias. Bone marrow aplasia occurred in all responding patients, but a differentiation effect is possible too. Maintenance therapy with LD Ara-C may be important for the two long-lasting CR.
骨髓增生异常综合征（MDS）是一组异质性疾病。骨髓有核细胞中原始细胞计数超过20%的患者生存时间短的风险很高。我们用小剂量阿糖胞苷（LD Ara-C）治疗了6例转化中原始细胞过多的难治性贫血（RAEBiT）患者。我们有1例部分缓解（PR），存活16周，2例完全缓解（CR），分别存活22个月和55 +个月。所有患者均以骨髓抑制为主，但不如白血病传统缓解诱导治疗严重。所有有反应的患者均发生了骨髓再生障碍，但也可能有分化效应。对于2例长期持续完全缓解的患者，LD Ara-C维持治疗可能很重要。
